Reduction of TRPV1 expression in the trigeminal system by botulinum neurotoxin type-A

Shimizu, Toshihiko; Shibata, Mamoru; Toriumi, Haruki; Iwashita, Tatsuo; Funakubo, Megumi; Sato, Hitoshi; Kuroi, Toshiya; Ebine, Taeko; Koizumi, Kenzo; Suzuki, Noriyuki

doi:10.1016/j.nbd.2012.07.010

Cited by 135 publications

(123 citation statements)

References 40 publications

Supporting

Mentioning

110

Contrasting

Unclassified

Order By: Relevance

“…In the same study it was shown that the increase of Ca 2+ concentration can overcome the BoNT/A-mediated inhibition of K + -stimulated CGRP release from trigeminal ganglion neurons (Meng et al, 2009). In cultured sensory ganglia BoNT/A prevented the SNARE-mediated TRPV1 translocation to the plasma membrane, which is suggested to contribute to its analgesic activity in vivo (Morenilla-Palao et al, 2004;Shimizu et al, 2012;Yiangou et al, 2011).…”

Section: 1 Ex Vivo and In Vitro Studiesmentioning

confidence: 99%

“…As the explanation for the effect on vesicular release (measured by FM4-64 dye), the authors proposed BoNT/A axonal transport from periphery and transcytosis within the trigeminal ganglion. Novel study reported reduction of TRPV1 expression within the trigeminal ganglion neurons projecting to cerebral dura mater after BoNT/A facial injection (Shimizu et al, 2012). Since neurons innervating dura and periphery are different, the authors suggested axonal transport of BoNT/A in primary sensory neurons but, also, a possible transcytosis of BoNT/A between different sensory neurons in the ganglion.…”

Section: 2 Effects Of Bont/a In Sensory Gangliamentioning

confidence: 99%

“…By targeting SNAP-25, BoNT/A may prevent the SNAREmediated translocation of receptors to plasma membrane, such as N-methy-D-aspartate receptor and transient receptor potential vanilloid 1 (TRPV1) MorenillaPalao et al, 2004;Shimizu et al, 2012). In addition, it may prevent the G protein interaction with SNARE-dependent exocytotic machinery (Gerachshenko et al, 2005).…”

Section: Additional Actions Of Bont/a Mediated By Snap-25mentioning

confidence: 99%

“…Since neurons innervating dura and periphery are different, the authors suggested axonal transport of BoNT/A in primary sensory neurons but, also, a possible transcytosis of BoNT/A between different sensory neurons in the ganglion. It was proposed that BoNT/A may modulate SNARE-mediated TRPV1 translocation to the plasma membrane of sensory neurons (Shimizu et al, 2012).…”

Section: 2 Effects Of Bont/a In Sensory Gangliamentioning

confidence: 99%

See 3 more Smart Citations

Botulinum toxin A, brain and pain

Matak

Lacković

2014

Progress in Neurobiology

149

114

View full text Add to dashboard Cite

Section: 1 Ex Vivo and In Vitro Studiesmentioning

confidence: 99%

Section: 2 Effects Of Bont/a In Sensory Gangliamentioning

confidence: 99%

Section: Additional Actions Of Bont/a Mediated By Snap-25mentioning

confidence: 99%

Section: 2 Effects Of Bont/a In Sensory Gangliamentioning

confidence: 99%

See 2 more Smart Citations

Botulinum toxin A, brain and pain

Matak

Lacković

2014

Progress in Neurobiology

149

114

View full text Add to dashboard Cite

“…Among these receptors, those that can potentially be used to treat trigeminal neuralgia include TRPV1, TRPV2, TRPV4, TRPM3, TRPM8 and TRPA1 55 . The vanilloid receptor TRPV1 is potentially inhibited after injection of BoNT/A in the region of the first trigeminal branch 56 . The effect of BoNT/A on TRPV1 expression in trigeminal neuralgia leads to reduced expression of CGRP and A: Nociception under physiological conditions -focused on the trigeminal nerve and its three branches (V1, V2, and V3); B: Constriction of the exposed infraorbital nerve (ION) -an experimental model of neuropathic pain.…”

Section: Neurobiological Mechanisms Responsible For the Antinociceptimentioning

confidence: 99%

OnabotulinumtoxinA for trigeminal neuralgia: a review of the available data

Kowacs

Utiumi

Nascimento

et al. 2015

Arq. Neuro-Psiquiatr.

View full text Add to dashboard Cite

Trigeminal neuralgia (TN) is a unilateral disorder characterized by brief electric-shock-like attacks of pain, abrupt in onset and termination and limited to the distribution of one or more divisions of the trigeminal nerve 1 . It is reported to have a prevalence of 0.1-0.2 per thousand and an incidence ranging from about 2 to 7.1/100 000/year and extending up to 20/100 000/year in individuals over 60 years of age. The condition is more common in women than in men (ratio 3:2) 2 . Treatment includes pharmacological therapy, usually with membrane stabilizers; invasive or minimally-invasive (mainly percutaneous procedures) surgical therapies; and radiosurgery 3 . In 2005, OnabotulinumtoxinA (BoNT/A) was reported to be effective for cases of TN that failed to respond to other therapies 4 . The therapeutic effect of BoNT/A in TN was first mentioned after a serendipitous finding by Wang and Jankovic 5. Reporting a case similar to the one that motivated a previous study by our group 4 , Jankovic described a patient who presented with hemifacial spasm and TN whose TN improved after treatment of the hemifacial spasm with BoNT/A. Since then, case reports and case series have been published in neurology, headache, pharmacology and pain medicine journals 6,7,8,9,10,11,12,13,14 . This literature, although suggesting the therapeutic effects of BoNT/A in TN, has been challenged 15 or even ignored by panels of experts 16,17 . The present review was undertaken to give readers an overview of the available evidence that BoNT/A has a therapeutic effect on TN. AbstrActTrigeminal neuralgia (TN) patients may develop side effects from centrally acting drugs, have contraindications for neurosurgical procedures, or experience relapse during conventional therapies. OnabotulinumtoxinA (BoNT/A) has been reported to be effective for TN, although this finding has been challenged. An overview of the available evidence based on a narrative/qualitative analysis of the literature is presented. About 90% of patients who receive BoNT/A show an improvement, a higher figure than that reported for the placebo effect of BoNT/A for other headaches. Tolerability of BoNT/A is good, and its few side-effects are transient. The articles reviewed were mainly case reports, case series and open-label trials; however, randomized controlled trials have endorsed the efficacy of BoNT/A for TN. This evidence, together with a better understanding of the analgesic mechanisms of BoNT/A and its proven efficacy in treating other pain syndromes, supports the use of this toxin as a therapeutic option for TN.Keywords: trigeminal neuralgia, botulinum neurotoxin type A, botulinum-A toxin, onabotulinumtoxinA, neuropathic pain. resumO Pacientes com neuralgia do trigêmeo (NT) podem apresentar efeitos colaterais decorrentes do uso de drogas psicoativas, contra-indicações a procedimentos neurocirúrgicos ou perda da eficácia destas terapias. A neurotoxina botulínica do tipo A (NTB/A) tem demonstrado ser eficaz no alívio da NT, ainda que este achado tenha sido contestado. Uma...

show abstract

Pain pathways and potential new targets for pain relief

Thyagarajan

2020

Biotech and App Biochem

View full text Add to dashboard Cite

Pain is an unpleasant sensory and emotional experience that affects a sizable percentage of people on a daily basis. Sensory neurons known as nociceptors built specifically to detect damaging stimuli can be found throughout the body. They transmit information about noxious stimuli from mechanical, thermal, and chemical sources to the central nervous system and higher brain centers via electrical signals. Nociceptors express various channels and receptors such as voltage-gated sodium and calcium channels, transient receptor potential channels, and opioid receptors that allow them to respond in a highly specific manner to noxious stimuli. Attenuating the pain response can be achieved by inhibiting or altering the expression of these pain targets. Achieving a deeper understanding of how these receptors can be affected at the molecular level can lead to the development of novel pain therapies. This review will discuss the mechanisms of pain, introduce the various receptors that are responsible for detecting pain, and future directions in pharmacological therapies.

show abstract

Reduction of TRPV1 expression in the trigeminal system by botulinum neurotoxin type-A

Cited by 135 publications

References 40 publications

Botulinum toxin A, brain and pain

Botulinum toxin A, brain and pain

OnabotulinumtoxinA for trigeminal neuralgia: a review of the available data

Pain pathways and potential new targets for pain relief

Contact Info

Product

Resources

About